Fig. 3: Kaplan-Meier survival curves for patients who received JAKi bridging vs. no bridging therapy prior to HCT. | Bone Marrow Transplantation

Fig. 3: Kaplan-Meier survival curves for patients who received JAKi bridging vs. no bridging therapy prior to HCT.

From: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study

Fig. 3

Eighty-nine patients received upfront HCT. The blue curve represents the OS probability of the 51 patients who received JAKi bridging therapy prior to HCT. The yellow curve represents that of patients who did not receive bridging therapy.

Back to article page